Helix BioMedix Inc. (OTCMKTS:HXBM) Short Interest Up 240.0% in August

Helix BioMedix Inc. (OTCMKTS:HXBM) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 204 shares, a growth of 240.0% from the August 15th total of 60 shares. Based on an average daily trading volume, of 280 shares, the short-interest ratio is presently 0.7 days. Approximately 0.1% of the shares of the company are short sold.

Helix BioMedix Stock Up 69.0%

HXBM traded up $2.45 during midday trading on Friday, reaching $6.00. The company had a trading volume of 400 shares, compared to its average volume of 302. Helix BioMedix has a 12-month low of $1.00 and a 12-month high of $6.50. The business has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $1.80.

About Helix BioMedix

Helix BioMedix, Inc (OTCMKTS: HXB M) is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic and supportive care products for cancer patients. The company’s research and development efforts center on leveraging the body’s innate immune system to enhance anti-tumor responses, with a pipeline that includes biologics designed to modulate immune checkpoints and activate phagocytic cells against tumor targets.

Operating from its headquarters in Cambridge, Massachusetts, Helix BioMedix applies proprietary discovery and screening platforms to identify and optimize lead candidates.